These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36196509)

  • 1. Clinical and laboratory responses to tigecycline in children.
    Aslan K; Kiliç Ö; Kiral E; Bozan G; Bör Ö; Dinleyici EÇ
    J Clin Pharm Ther; 2022 Oct; 47(10):1585-1590. PubMed ID: 36196509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Tigecycline in Pediatric Patients With Infections Predominantly Due to Extensively Drug-Resistant Gram-Negative Bacteria.
    Iosifidis E; Violaki A; Michalopoulou E; Volakli E; Diamanti E; Koliouskas D; Antachopoulos C; Drossou-Agakidou V; Sdougka M; Roilides E
    J Pediatric Infect Dis Soc; 2017 Jun; 6(2):123-128. PubMed ID: 27000866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary experience with tigecycline treatment for severe infection in children.
    Ye S; Zhang C; Lin S
    Eur J Pediatr; 2018 Oct; 177(10):1489-1496. PubMed ID: 30008076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Tigecycline to Treat Multidrug-resistant Infections in Pediatrics: An Evidence Synthesis.
    Sharland M; Rodvold KA; Tucker HR; Baillon-Plot N; Tawadrous M; Hickman MA; Raber S; Korth-Bradley JM; Díaz-Ponce H; Wible M
    Pediatr Infect Dis J; 2019 Jul; 38(7):710-715. PubMed ID: 31192975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preliminary experience of tigecycline treatment for infection in children with hematologic malignancies.
    Lin S; Zhang C; Ye S
    Int J Clin Pharm; 2018 Oct; 40(5):1030-1036. PubMed ID: 30051224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
    Sader HS; Jones RN; Dowzicky MJ; Fritsche TR
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tigecycline therapy in pediatric patients with multidrug resistant bacteremia.
    Ozkaya-Parlakay A; Gulhan B; Kanik-Yuksek S; Guney D; Gonulal D; Demirtas G; Tezer H; Unal S; Senel E
    Enferm Infecc Microbiol Clin (Engl Ed); 2020 Dec; 38(10):471-473. PubMed ID: 32081452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro activity of tigecycline against multidrug-resistant Gram negative bacteria: The experience of a university hospital.
    Elnasser Z; Elsamarneh R; Obeidat H; Amarin Z; Jaradat S; Kaplan N
    J Infect Public Health; 2021 Apr; 14(4):478-483. PubMed ID: 33743369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Best tigecycline dosing for treatment of infections caused by multidrug-resistant pathogens in critically ill patients with different body weights.
    Ibrahim MM; Abuelmatty AM; Mohamed GH; Nasr MA; Hussein AK; Ebaed MED; Sarhan HA
    Drug Des Devel Ther; 2018; 12():4171-4179. PubMed ID: 30584281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tigecycline use in serious nosocomial infections: a drug use evaluation.
    Bassetti M; Nicolini L; Repetto E; Righi E; Del Bono V; Viscoli C
    BMC Infect Dis; 2010 Sep; 10():287. PubMed ID: 20920273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of tigecycline and its role in the era of antibiotic resistance.
    Rossi F; Andreazzi D
    Braz J Infect Dis; 2006 Jun; 10(3):203-16. PubMed ID: 17568854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy of tigecycline used as monotherapy or in combination regimens for complicated infections with documented involvement of multiresistant bacteria.
    Heizmann WR; Löschmann PA; Eckmann C; von Eiff C; Bodmann KF; Petrik C
    Infection; 2015 Feb; 43(1):37-43. PubMed ID: 25367409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Characteristics of epidemiology and antimicrobial resistance of gram-negative bacterial bloodstream infections in children].
    Dong L; Zhang XY; Li CC; Li Z; Xia YQ
    Zhonghua Er Ke Za Zhi; 2017 Sep; 55(9):683-688. PubMed ID: 28881515
    [No Abstract]   [Full Text] [Related]  

  • 14. [Microbiological profiles of pathogens causing nosocomial bacteremia in 2011, 2013 and 2016].
    Wang X; Zhao C; Li H; Chen H; Jin L; Wang Z; Liao K; Zeng J; Xu X; Jin Y; Su D; Liu W; Hu Z; Cao B; Chu Y; Zhang R; Luo Y; Hu B; Wang H
    Sheng Wu Gong Cheng Xue Bao; 2018 Aug; 34(8):1205-1217. PubMed ID: 30152206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Life-threatening coagulopathy and hypofibrinogenaemia induced by tigecycline in a patient with advanced liver cirrhosis.
    Rossitto G; Piano S; Rosi S; Simioni P; Angeli P
    Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):681-4. PubMed ID: 24667348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tigecycline salvage therapy for critically ill children with multidrug-resistant/extensively drug-resistant infections after surgery.
    Song Y; Hu L; Shu Q; Ye J; Liang J; Chen X; Tan L
    Int J Infect Dis; 2018 Oct; 75():82-88. PubMed ID: 30125690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance trends and in vitro activity of tigecycline and 17 other antimicrobial agents against Gram-positive and Gram-negative organisms, including multidrug-resistant pathogens, in Germany.
    Kresken M; Becker K; Seifert H; Leitner E; Körber-Irrgang B; von Eiff C; Löschmann PA;
    Eur J Clin Microbiol Infect Dis; 2011 Sep; 30(9):1095-103. PubMed ID: 21347680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial activity of tigecycline against nosocomial pathogens in Pakistan: a multicenter study.
    Ahmed A; Zafar A; Mirza S
    J Pak Med Assoc; 2009 Apr; 59(4):240-2. PubMed ID: 19402288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections.
    Bradford PA; Weaver-Sands DT; Petersen PJ
    Clin Infect Dis; 2005 Sep; 41 Suppl 5():S315-32. PubMed ID: 16080070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tigecycline in the Treatment of Patients with Necrotizing Skin and Soft Tissue Infections Due to Multiresistant Bacteria.
    Eckmann C; Heizmann W; Bodmann KF; von Eiff C; Petrik C; Loeschmann PA
    Surg Infect (Larchmt); 2015 Oct; 16(5):618-25. PubMed ID: 26115414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.